{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-015840","form_type":"8-K","ticker":"ACRS","cik":"0001557746","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2023-09-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.289688+00:00","generated_at":"2026-06-10T14:44:32.743110+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aclaris reports positive Phase 1 MAD data for ATI-2138; advances to Phase 2a in ulcerative colitis","bullets":["ATI-2138 well tolerated in 60-subject MAD trial; no serious adverse events; mild headache and diarrhea only events in >1 subject.","Dose-proportional PK and near-maximal inhibition of ITK and JAK3 biomarkers achieved at 30 mg total daily dose.","Company to start Phase 2a proof-of-concept in ulcerative colitis in early 2024; evaluating second PoC in another T-cell mediated disease.","CEO highlights KINect discovery engine; upcoming Phase 2 data for zunsemetinib (RA) and ATI-1777 (atopic dermatitis) expected late 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-015840","json":"https://secwatch.observer/filing/0001558370-23-015840.json","markdown":"https://secwatch.observer/filing/0001558370-23-015840.md","text":"https://secwatch.observer/filing/0001558370-23-015840.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1557746/000155837023015840/0001558370-23-015840-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1557746/000155837023015840/acrs-20230918x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T14:44:32.743110+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}